From Carrier Effect to Collagen Remodeling: Toward Endpoint-Specific Longevity Assessment in Polycaprolactone-Based Collagen-Stimulating Fillers

A polycaprolactone filler works in two acts, and for years the marketing has credited only the second one. In the weeks after injection, the volume a patient sees comes mostly from carboxymethylcellulose (CMC) gel, the carrier that suspends roughly 30% PCL microspheres in a 70% gel base. That gel resorbs within four to eight weeks by most estimates, sometimes stretching to two or three months. Only after the carrier is gone does the polymer itself take over: PCL microspheres, typically 25 to 50 microns wide, hydrolyze slowly over 12 to 24 months or longer, and it is this slow breakdown that is thought to stimulate the body's own collagen production.

A new paper in the Journal of Cosmetic Dermatology, titled "From Carrier Effect to Collagen Remodeling: Toward Endpoint-Specific Longevity Assessment in Polycaprolactone-Based Collagen-Stimulating Fillers," argues that the industry has been sloppy about which of these two effects a given "longevity" number actually describes. A filler advertised as lasting 18 to 24 months may be reporting the gel's bulking effect, the polymer's collagen effect, or an unlabeled blend of both, depending on when and how the measurement was taken.

The measurement method turns out to matter enormously. A study on PCL filler published through Dovepress and indexed on PubMed Central found that injected volume increased by 50% to 150% over the original amount at the two-year mark, a figure researchers pointed to as proof the collagen-stimulating effect was real and substantial. But that number was generated with a specific imaging approach, and the broader filler literature shows how much the choice of instrument can move the result. In studies of hyaluronic acid fillers, a different class of product but a comparable measurement problem, 3D surface imaging reported 50% to 86% persistence at 24 months, while MRI on the same class of filler detected presence only through 12 months. Same substance, same rough timeframe, very different verdicts, depending on whether the machine was reading surface contour or tissue composition.

That gap between what a scanner sees and what a patient feels compounds the problem. Research on filler outcomes generally has found that patient-reported satisfaction tends to decline before objective imaging shows any measurable volume loss, meaning the subjective and objective clocks for "how long a filler lasts" run at different speeds. A framework that reports a single duration number, without specifying whether it is tracking gel volume, collagen density, or how the patient feels in the mirror, is answering a question that was never precisely asked.

There is also a complication in the collagen story itself. A 2020 JOCD retrospective covering 1,111 PCL treatments reported low complication rates and no nodules or granulomas in that series, a track record often cited in support of the product's safety. Since then, case reports and a 2026 ultrasonographic case series have described delayed-onset nodules and granulomatous reactions to PCL filler in some patients, occasionally triggered by viral illness or by COVID-19 vaccination. The relevance to endpoint-specific measurement is direct: a granulomatous, foreign-body reaction can look like durable volume on ultrasound or on clinical exam, indistinguishable in some cases from the neocollagenesis the product is designed to produce. An imaging endpoint alone cannot always tell a clinician which process it is looking at.

PCL fillers sold under the Ellansé name, along with poly-L-lactic acid competitors like Sculptra and Lanluma, are CE-marked and used widely across Europe and Asia but remain unapproved by the FDA for cosmetic use in the United States, a gap that shapes where the clinical data behind papers like this one tends to originate. A multicenter post-marketing trial (NCT06243315) is currently tracking long-term safety outcomes for Ellansé-S in nasolabial fold treatment, part of the same evidence base the endpoint-specific framework would need to draw on if it is to move from proposal to standard practice.

Separately, a companion 2026 JOCD paper by Seo and colleagues examined a liquid-form PCL injection and measured its effect through dermal thickness and collagen content on biopsy, a histological endpoint distinct from both the volumetric imaging and the patient-satisfaction surveys described above. Set next to each other, the three approaches (volumetric scan, biopsy sample, patient questionnaire) describe three different things that could each reasonably be called the filler's "longevity," and a manufacturer's marketing claim rarely specifies which one it means.